Linc AB reports significant shareholding in Oncoinvent ASA
Linc AB has declared a significant shareholding in Oncoinvent ASA, following the company's private placement and retail offering in September 2026. The disclosure details Linc AB's role in lending shares to facilitate the offering.
Linc AB has announced a substantial shareholding in Oncoinvent ASA, stemming from the company's private placement and retail offering conducted in September 2026. Oncoinvent ASA successfully raised capital by issuing 1,650,000 new shares at a price of NOK 90.00 per share.
The disclosure specifies Linc AB's involvement in the share lending agreement related to the offering. Linc AB agreed to lend 555,362 shares to the managers of the offering, facilitating the delivery versus payment process. This arrangement is a common practice to ensure the smooth distribution of newly issued shares.
Oncoinvent ASA is focused on developing novel cancer therapies. The company's recent capital raise through the private placement and retail offering is intended to strengthen its financial position for ongoing research and development activities. The goal is to advance oncology treatments through scientific innovation.
This announcement is part of the regulatory requirement for major shareholders to disclose their holdings in publicly listed companies. Such disclosures provide transparency regarding the ownership structure and potential influence of significant investors in the company.